* Says OMS201 safe and well-tolerated
* Says study did not assess efficacy
Dec 29 Omeros Corp (OMER.O) said its
experimental drug for patients undergoing urological surgery
showed the drug was safe and well-tolerated in an
The trial was designed to test the safety of OMS201 and see
how higher concentrations of the drug were absorbed, the
company said in a statement.
During the study, the drug -- a combination of an
anti-inflammatory agent and a muscle relaxant -- was
administered to patients undergoing ureteroscopy for removal of
ureteral or renal stones.
Ureteroscopy is a procedure to examine the insides of the
kidney and the tubes leading from the kidney to the bladder.
The trial also explored potential efficacy endpoints, but
was not powered to assess efficacy, Omeros said.
The company's shares, which have gained more than 30
percent over the last four months, closed at $8.02 Monday on
(Reporting by Shailesh Kuber in Bangalore; Editing by Vyas